Form 4: CRISPR Therapeutics Director Katherine High Granted 13,000 Stock Options

Katherine A. High, a Director at CRISPR Therapeutics AG, was granted 13,000 stock options with an exercise price of $38.57, vesting over 12 months.

Summary

• Katherine A. High, a Director of CRISPR Therapeutics AG (CRSP), was granted 13,000 stock options on June 5, 2025.
• The stock options have an exercise price of $38.57 per common share.
• The options will vest 100% in 12 equal monthly installments, commencing on June 30, 2025.
• The final installment will vest on the earlier of the one-year anniversary of the grant date (June 5, 2026) or the date of the 2026 Annual General Meeting of Shareholders.
• The options have an expiration date of June 5, 2035.
• Following this transaction, Katherine A. High beneficially owns 13,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive event as it aligns the director's interests with the long-term performance of the company and shareholder value, reflecting standard compensation practices. It does not indicate any operational or financial issues.

Positives

• The grant of stock options to a director aligns their interests with the long-term performance and shareholder value of CRISPR Therapeutics AG.
• This is a standard component of director compensation, indicating continued commitment and incentivization for the director.

Future Outlook

The future outlook related to this filing involves the vesting of the 13,000 stock options over the next 12 months, providing Katherine A. High with the right to purchase CRISPR Therapeutics common shares at the exercise price of $38.57 until June 5, 2035.

Industry Context

The grant of stock options to directors is a common and standard practice across various industries, including biotechnology and pharmaceuticals, as a form of long-term incentive compensation. This aligns the interests of the director with the company's performance and shareholder returns.

Comparison to Industry Standards

• The grant of stock options as part of director compensation is a widely accepted practice in the biotechnology and pharmaceutical sectors, similar to companies like Vertex Pharmaceuticals or Moderna, which also utilize equity-based incentives to attract and retain talent and align interests.
• The vesting schedule of 12 equal monthly installments is a common approach for equity grants, providing a steady incentive over a defined period, comparable to vesting schedules seen at other publicly traded biotech firms.

Related Party Transactions

• The grant of stock options to Katherine A. High, a Director of CRISPR Therapeutics AG, constitutes a related party transaction as it involves compensation provided to a member of the company's board of directors.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with the long-term performance of the company, potentially benefiting shareholders through improved governance and strategic decisions.
• Employees: While not directly impacting general employees, such compensation practices are part of a broader corporate governance framework that can influence overall company culture and talent retention strategies.

Next Steps

• The stock options will continue to vest in monthly installments beginning June 30, 2025.
• Katherine A. High may choose to exercise these options at any time after they vest and before their expiration date of June 5, 2035.

Key Dates

Keywords

CRISPR Therapeutics, CRSP, Stock Option, Insider Transaction, Form 4, Director Compensation, Equity Grant, Vesting